Key Highlights:

  • Revenue increased 10.7% to AUD 3.32bn.
  • Underlying EBIT rose 19.3% to AUD 599.0mn.
  • Underlying net profit grew 25.8% to AUD 381.2mn.
  • Minerals organic growth guidance for FY2027 is 13% to 15%.

ALS operates in an unglamorous but powerful niche: the testing, inspection and certification of everything from mineral drill core to food and drinking water. Its FY2026 result, for the year ended 31 March 2026 and reported in May, was a record, driven by a surging minerals Business and steady expansion in life sciences. As at late August, it remains the company's most recent full-year scorecard, and it reinforces the case that ALS is a structural grower hiding inside a cyclical wrapper.

Latest Developments

The engine of the result was Commodities, and within it the geochemistry business that tests exploration samples for miners. A wave of exploration activity, particularly in gold and copper, drove strong organic sample-volume growth and healthy pricing.

Life Sciences, the larger and more defensive division spanning environmental, food and pharmaceutical testing, grew more modestly but lifted margins. Management completed the transformation of its Nuvisan pharmaceutical operation and signalled new contracts to support the year ahead. The overall message was one of disciplined growth and Margin expansion across both halves of the business.

FY2026 Numbers at a Glance

Revenue rose 10.7 % to AAUD 3,320.1 mn. Underlying EBIT increased 19.3 % to AAUD 599.0 mn, lifting the group margin to 18.0 %, while underlying net profit grew 25.8 % to AAUD 381.2 mn. Basic Earnings Per Share rose 21.2 % to 75.7 cents.

The full-year Dividend was 42.5 cents per share, comprising a 19.4-cent interim and a 23.1-cent final, a payout of about 57 % of underlying profit. Commodities Revenue jumped 18.8 % to AAUD 1,294.2 mn at a 29.5 % EBIT margin, with geochemistry organic revenue up 22.7 %, while Life Sciences revenue rose 6.0 % to AAUD 2,025.9 mn at a 14.6 % margin. The minerals-testing margin expanded to about 33 %, illustrating the powerful Operating Leverage that comes when sample volumes rise against a largely fixed laboratory cost base.

What Could Drive ALS Ltd Next?

Guidance frames continued momentum. ALS is targeting mid to high single-digit organic revenue growth at group level for FY2027, with minerals organic growth of 13 to 15 % and an even stronger 15 to 17 % flagged for the first half.

The key catalysts are the depth and duration of the exploration cycle, ongoing margin gains from operating leverage in minerals, and a recovery in environmental testing in the Americas. Bolt-on acquisitions in the fragmented testing market remain a further avenue for growth, and the completed turnaround of the Nuvisan pharmaceutical operation is expected to support the life-sciences contribution as new contracts ramp.

Key Risks to Watch

Commodities earnings are geared to mineral exploration spending, which rises and falls with Commodity prices and junior-miner funding conditions. A downturn in exploration would quickly slow the division's growth.

Life Sciences faces softer patches, with environmental testing having weakened in the second half. The partial franking of dividends reflects the group's substantial offshore earnings, and currency movements, wage Inflation and integration of acquisitions add further variables to the outlook.

Investor Takeaway

ALS delivered record revenue, margins and earnings in FY2026, with a booming geochemistry business complementing steadier life-sciences growth. The result underlines a business with genuine operating leverage and structural Demand for testing services. The debate for the market is how much of the minerals strength is cyclical exuberance versus durable Volume growth. With guidance pointing to continued double-digit expansion in minerals, ALS enters FY2027 with momentum, tempered by its sensitivity to the Mining cycle.